Logo image of ALCJ.PA

CROSSJECT (ALCJ.PA) Stock Overview

EPA:ALCJ - FR0011716265 - Common Stock

1.402 EUR
-0.03 (-1.96%)
Last: 9/3/2025, 7:00:00 PM

ALCJ.PA Key Statistics, Chart & Performance

Key Statistics
52 Week High2.75
52 Week Low0.72
Market Cap71.18M
Shares50.77M
Float40.58M
Yearly DividendN/A
Dividend YieldN/A
EPS(TTM)-0.28
PEN/A
Fwd PE21.51
Earnings (Next)09-22 2025-09-22
IPO02-20 2014-02-20
Sector
GICS SectorHealth Care
GICS IndustryHealth Care Equipment & Supplies
GICS IndustryGroupHealth Care Equipment & Services
GICS SubIndustryHealth Care Supplies


ALCJ.PA short term performance overview.The bars show the price performance of ALCJ.PA in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months -5 -10 -15 -20 -25

ALCJ.PA long term performance overview.The bars show the price performance of ALCJ.PA in the last 1, 2 and 3 years. 1 year 2 years 3 years -20 -40 -60

The current stock price of ALCJ.PA is 1.402 EUR. In the past month the price decreased by -4.5%. In the past year, price decreased by -35.98%.

CROSSJECT / ALCJ Daily stock chart

ALCJ.PA Competitors/Peers

The largest stocks on the EU markets in the "Health Care Supplies" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
EL.PA ESSILORLUXOTTICA 37.66 118.38B
ESL.DE ESSILORLUXOTTICA 37.55 118.04B
1EL.MI ESSILORLUXOTTICA 37.45 117.72B
2U3.DE ALCON INC 26.26 33.99B
CBHD.DE COLOPLAST-B 32.64 17.49B
GENT.OL GENTIAN DIAGNOSTICS ASA 20.45 848.10M
GBT.PA GUERBET 15.13 242.94M
AFME.PA AFFLUENT MEDICAL SA N/A 57.84M
PTP.DE PENTIXAPHARM HOLDING AG N/A 42.31M

About ALCJ.PA

Company Profile

ALCJ logo image Crossject SA manufactures and markets needle free injection system. The company is headquartered in Dijon, Bourgogne-Franche-Comte and currently employs 108 full-time employees. The company went IPO on 2014-02-20. The firm specializes in needle-free, pre-filled, single-use injection systems for intradermal, subcutaneous, and intramuscular applications for pharmaceutical companies. Is also has a pipeline and three drugs in the preclinical or clinical phase of research. The firm's products, which are based on well-known injectable drugs (chemicals and biologics), are designed to enhance patients' safety, compliance, and comfort. The firm has industrial partnerships with Hirtenberger and Recipharm. The company provides Zeneo, a prefilled and single-use device that can be used for intradermal, subcutaneous and intramuscular injections.

Company Info

CROSSJECT

Parc Mazen-Sully, 6 Rue Pauline Kergomard

Dijon BOURGOGNE-FRANCHE-COMTE FR

Employees: 106

ALCJ Company Website

ALCJ Investor Relations

Phone: 33380549850

CROSSJECT / ALCJ.PA FAQ

What is the stock price of CROSSJECT today?

The current stock price of ALCJ.PA is 1.402 EUR. The price decreased by -1.96% in the last trading session.


What is the ticker symbol for CROSSJECT stock?

The exchange symbol of CROSSJECT is ALCJ and it is listed on the Euronext Paris - Matif exchange.


On which exchange is ALCJ.PA stock listed?

ALCJ.PA stock is listed on the Euronext Paris - Matif exchange.


What is the price forecast or stock price prediction for CROSSJECT stock?

9 analysts have analysed ALCJ.PA and the average price target is 3.37 EUR. This implies a price increase of 140.09% is expected in the next year compared to the current price of 1.402. Check the CROSSJECT stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is CROSSJECT worth?

CROSSJECT (ALCJ.PA) has a market capitalization of 71.18M EUR. This makes ALCJ.PA a Micro Cap stock.


How many employees does CROSSJECT have?

CROSSJECT (ALCJ.PA) currently has 106 employees.


What are the support and resistance levels for CROSSJECT (ALCJ.PA) stock?

CROSSJECT (ALCJ.PA) has a support level at 1.39 and a resistance level at 1.65. Check the full technical report for a detailed analysis of ALCJ.PA support and resistance levels.


Is CROSSJECT (ALCJ.PA) expected to grow?

The Revenue of CROSSJECT (ALCJ.PA) is expected to grow by 308.97% in the next year. Check the estimates tab for more information on the ALCJ.PA EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy CROSSJECT (ALCJ.PA) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does CROSSJECT (ALCJ.PA) stock pay dividends?

ALCJ.PA does not pay a dividend.


When does CROSSJECT (ALCJ.PA) report earnings?

CROSSJECT (ALCJ.PA) will report earnings on 2025-09-22.


What is the Price/Earnings (PE) ratio of CROSSJECT (ALCJ.PA)?

CROSSJECT (ALCJ.PA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.28).


ALCJ.PA Technical Analysis


Chartmill TA Rating
Chartmill Setup Rating

ALCJ.PA Fundamental Analysis

ChartMill assigns a fundamental rating of 1 / 10 to ALCJ.PA. ALCJ.PA has a bad profitability rating. Also its financial health evaluation is rather negative.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

ALCJ.PA Financial Highlights

Over the last trailing twelve months ALCJ.PA reported a non-GAAP Earnings per Share(EPS) of -0.28. The EPS decreased by -23.99% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -40.53%
ROE -470.75%
Debt/Equity 6.53
Chartmill High Growth Momentum
EPS Q2Q%-20.65%
Sales Q2Q%-100%
EPS 1Y (TTM)-23.99%
Revenue 1Y (TTM)-100%

ALCJ.PA Forecast & Estimates

9 analysts have analysed ALCJ.PA and the average price target is 3.37 EUR. This implies a price increase of 140.09% is expected in the next year compared to the current price of 1.402.

For the next year, analysts expect an EPS growth of 125.14% and a revenue growth 308.97% for ALCJ.PA


Analysts
Analysts84.44
Price Target3.37 (140.37%)
EPS Next Y125.14%
Revenue Next Year308.97%

ALCJ.PA Ownership

Ownership
Inst Owners0.56%
Ins OwnersN/A
Short Float %N/A
Short RatioN/A